Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13597040 | 0.96 | DPP4 (0.47) | ACHEDPP4DPP8DPP7SLC6A3 | |
| SCHEMBL6778994 | 0.86 | ACHE (0.46) | ACHEDPP8DPP7SLC6A3 | |
| SCHEMBL6773131 | 0.86 | ACHE (0.46) | ACHESLC6A3 | |
| SCHEMBL13597027 | 0.85 | DPP4 (0.58) | DPP4SLC6A3 | |
| SCHEMBL13597034 | 0.84 | DPP4 (0.56) | DPP4SLC6A3 | |
| SCHEMBL13597035 | 0.84 | DPP4 (0.56) | DPP4SLC6A3 | |
| SCHEMBL13597030 | 0.84 | DPP4 (0.56) | DPP4SLC6A3 | |
| SCHEMBL16226399 | 0.83 | ACHE (0.51) | ACHEDPP8DPP7SLC6A3 | |
| SCHEMBL13597041 | 0.81 | CYP2D6 (0.47) | DPP4SLC6A3 | |
| SCHEMBL13597015 | 0.81 | DPP4 (0.63) | DPP4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | ACHE 1285/4885DPP4 4440/4885DPP8 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.